Literature DB >> 16283446

MALT lymphoma presenting as a meningioma.

Halim Abboud, Antoine Carpentier, Nadine Martin-Duverneuil, Michele Kujas, Khe Hoang-Xuan.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16283446     DOI: 10.1007/s11060-005-1940-2

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


× No keyword cloud information.
  2 in total

1.  Primary low-grade B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) arising in dura.

Authors:  N Kambham; Y Chang; A Y Matsushima
Journal:  Clin Neuropathol       Date:  1998 Nov-Dec       Impact factor: 1.368

2.  Primary low-grade B-cell lymphoma of the dura: a mucosa associated lymphoid tissue-type lymphoma.

Authors:  S Kumar; D Kumar; E P Kaldjian; S Bauserman; M Raffeld; E S Jaffe
Journal:  Am J Surg Pathol       Date:  1997-01       Impact factor: 6.394

  2 in total
  3 in total

1.  Chemotherapy is an efficient treatment in primary CNS MALT lymphoma.

Authors:  Clément Desjardins; Delphine Larrieu-Ciron; Sylvain Choquet; Karima Mokhtari; Frédéric Charlotte; Lucia Nichelli; Bertrand Mathon; Guido Ahle; Magali Le Garff-Tavernier; Andrea Morales-Martinez; Caroline Dehais; Khê Hoang-Xuan; Caroline Houillier
Journal:  J Neurooncol       Date:  2022-06-20       Impact factor: 4.506

2.  Modern techniques of magnetic resonance in the evaluation of primary central nervous system lymphoma: contributions to the diagnosis and differential diagnosis.

Authors:  Antonio José da Rocha; Bruno Vasconcelos Sobreira Guedes; Talita Maira Bueno da Silveira da Rocha; Antonio Carlos Martins Maia Junior; Carlos Sérgio Chiattone
Journal:  Rev Bras Hematol Hemoter       Date:  2015-12-31

Review 3.  A Rare Case of Composite Dural Extranodal Marginal Zone Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Authors:  Mark Bustoros; Benjamin Liechty; David Zagzag; Cynthia Liu; Timothy Shepherd; Deborah Gruber; Bruce Raphael; Dimitris G Placantonakis
Journal:  Front Neurol       Date:  2018-04-24       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.